A
ctive surveillance (AS) is now the preferred approach for managing newly diagnosed, low-risk prostate cancer (1, 2) . A recent guideline from the American Society of Clinical Oncology (2) supports the use of AS for low-risk prostate cancer and provides recommendations about the target population and surveillance protocol. However, the recommendations lack specific information about how AS should be implemented.
Several studies in North America (3) (4) (5) (6) and Europe (7) are investigating the outcomes of AS, but they involve different populations, follow-up durations, inclusion criteria, surveillance protocols, and definitions of progression that lead to treatment referral. Having data from several AS cohorts provides an opportunity to learn more about disease progression on AS. Recent analyses within specific cohorts (6, 8, 9 ) have pointed to prostate-specific antigen (PSA) level, number of prior stable biopsy results, PSA density, and history of any negative biopsy results as important predictors of progression. However, differences in AS implementation and adherence across cohorts preclude comparison of progression risks and prevent direct integration of results to inform best practices (10).
This article brings together individual-level data from 4 of the largest North American AS studies to compare and integrate their information about prostate cancer progression on AS. We evaluated whether progression rates were consistent across cohorts after standardizing inclusion criteria and the definition of progression and after controlling for variable surveillance intervals and risks for competing treatments. In addition, we examined the expected consequences of more versus less frequent biopsies across AS studies. This cross-cohort analysis is critical to assessing representativeness of individual studies and to developing sound AS guidelines that balance timely intervention with the morbidity from intensive surveillance. veillance strategies, and conditions for referral to treatment are summarized in Table 1 .
Johns Hopkins University
The Johns Hopkins University (JHU) (4) study began enrollment in 1995. Eligibility criteria are PSA density less than 0.15 μg/L per mL, clinical stage T1c disease or lower, a Gleason score (GS) between 2 and 6, at most 2 positive biopsy cores, and at most 50% tumor in any single core. Men are monitored with a PSA test and digital rectal examination every 6 months and annual biopsies. Curative intervention is recommended for disease progression, defined as any adverse change on prostate biopsy.
Canary Prostate Active Surveillance Study
The Canary Prostate Active Surveillance Study (PASS) (3) began enrollment in 2008. Eligibility criteria are clinical stage T1 or T2 disease and either a 10-core biopsy less than 1 year before enrollment or at least 2 biopsies, 1 of which must be less than 1 year before enrollment (3) . Men are monitored with PSA tests every 3 months, a digital rectal examination every 6 months, and biopsies at 6 to 12, 24, 48, and 72 months after enrollment. Curative intervention is recommended if either biopsy GS or volume increases (from ≤33% to >33% of cores containing cancer).
University of Toronto
The University of Toronto (UT) (5) study began enrollment in 1995. Between 1995 and 1999, eligibility criteria were a PSA level of 10 μg/L or less and a GS between 2 and 6 for men younger than 70 years and a PSA level of 15 μg/L or less and a GS of at most 3 + 4 = 7 for men aged 70 years or older. In January 2000, eligibility criteria were expanded to include PSA levels of 20 μg/L or less and GSs of at most 3 + 4 = 7 in men with substantial comorbid conditions or a life expectancy less than 10 years. Men are monitored with PSA tests every 3 months for 2 years and every 6 months thereafter. A confirmatory biopsy is done within 12 months of the initial biopsy and then every 3 to 4 years until the patient reaches age 80 years. Curative intervention is recommended in cases of histologic upgrading on repeated biopsy or clinical progression between biopsies (or PSA kinetics before 2009).
University of California, San Francisco
The University of California, San Francisco (UCSF) (6), study began enrollment in 1990. Eligibility criteria 
Statistical Analysis

Exclusion Criteria and End Point Definitions
Patients diagnosed before 1995, older than 80 years at enrollment, or with a GS of 7 or more at diagnosis were excluded from the analysis to obtain a more homogeneous population (Supplement Table 1 , available at Annals.org). Further, we standardized the definition of disease progression to focus exclusively on biopsy upgrading-that is, the first point at which a biopsy GS of 7 or more is reached. We also defined competing treatments as initiation of active treatment in the absence of biopsy upgrading, such as in response to increased biopsy volume or increased PSA growth. Accounting for differences in risks for competing treatments is important because cohorts with a high frequency of competing treatments may seem to have a lower risk for biopsy upgrading than similar cohorts with a low frequency of competing treatments even if their underlying risk for biopsy upgrading is similar.
Estimating the Underlying Risks for Upgrading
The empirical risk for upgrading is affected by both the surveillance protocol and the frequency of competing treatment. Our first objective was to compare underlying risks for upgrading across surveillance cohorts-risks that would be seen in the absence of competing treatments. A standard approach for obtaining underlying risks, the Kaplan-Meier curve, is valid only if the competing event is independent of the event of interest. In the AS setting, upgrading and treatment initiation may be dependent. For example, if patients with higher PSA levels or PSA velocities tend to initiate treatment more frequently, this could induce dependence between initiating treatment and upgrading risk. When a dependent competing risk is present, the Kaplan-Meier approach is biased (11, 12) . However, a commonly used alternative, the cumulative incidence estimate, captures the risk for the event of interest in the presence of the competing event and can therefore be sensitive to the competing risk. For example, 2 cohorts could have the same underlying risk for upgrading, but 1 with a higher incidence of competing treatment would seem to have a lower incidence of upgrading.
To overcome this problem, we first evaluated the dependence of the 2 events using a regression model that allowed both events to depend on patient age and PSA kinetics. Allowing risks for both upgrading and competing treatment to depend on these common patient variables enabled us to capture their potential dependence on each other. For example, if the risks for upgrading and treatment initiation both increased with PSA velocity, the 2 risks would be positively correlated. In practice, we estimated a "joint model" for the evolution of the patient variables and the risks for upgrading and treatment initiation (13) (14) (15) . After fitting the joint model, we extracted the risk for upgrading in the absence of competing treatments using standard statistical formulas for obtaining marginal from conditional data summaries. This avoided the limitations of the Kaplan-Meier and cumulative incidence approaches.
The joint model had the following 3 components. First, the PSA model was a linear mixed-effects model for log PSA that captured heterogeneity in patient PSA kinetics, which comprised baseline PSA and PSA velocity, defined as the annual percentage change in the PSA level. Second, the model for time to upgrading was a Weibull regression that modeled the risk for upgrading given patient age and PSA kinetics. This model assumed that biopsy GS had no misclassification error. Thus, patients with all biopsy GSs between 2 and 6 were right censored for the event of upgrading (that is, their upgrading event could occur only after the end of their follow-up), and patients with an observed biopsy GS of 7 or higher must have upgraded after the prior biopsy but before this biopsy. Third, the model for time to competing treatment was another Weibull regression that modeled the risk for treatment initiation given patient age and PSA kinetics.
We used Bayesian methods to estimate the 3 models simultaneously (Section 1 of the Supplement, available at Annals.org). We did not attempt to model pathologic GS because previous work encountered substantial difficulties in doing so using serial biopsies among men receiving AS (16) .
Predicting Consequences Under More Versus Less Intensive Surveillance Protocols
Using the fitted joint model, we simulated times to upgrading in each cohort in the absence of competing treatments. We then superimposed surveillance protocols that involved regular biopsies every 1, 2, 3, and 4 years to determine the earliest point at which a biopsy would detect the upgrade. To acknowledge the clinical value of a confirmatory biopsy, we also considered biopsies every 2 years starting after the first confirmatory biopsy (that is, 1 year after enrollment). The model predictions consisted of the average number of biopsies and the average time delay between detection under each protocol and detection with annual biopsies. To project the consequences of delaying the detection of biopsy upgrade, we harnessed a previously developed algorithm (17) that translates delays in diagnosis and treatment into relative risks for prostate cancer death. Specifically, the algorithm applies an established nomogram for prostate cancer death given the predicted change in PSA level due to the delay since the true point of biopsy upgrade, while keeping other prognostic covariates (such as volume) constant. Our projecUpgrading in Four Prostate Cancer Active Surveillance Cohorts ORIGINAL RESEARCH 
Role of the Funding Source
The funding sources had no role in the design, conduct, or reporting of this study.
RESULTS
Empirical Risks for Upgrading
Descriptive statistics for the 4 cohorts are shown in Table 2 . Supplement Table 1 reports the number of patients omitted by our exclusion criteria to obtain more similar patient populations; the resulting sample consisted of 699 patients from the JHU cohort, 613 from PASS, 421 from UT, and 843 from UCSF. Figure 1 presents the empirical cumulative incidence of upgrading across cohorts after applying the exclusions. (Supplement Figure 1 , available at Annals.org, shows corresponding curves before exclusions.) The empirical cumulative incidence represents the cumulative risk for upgrading in the presence of competing treatment; that is, if treatment is initiated for a given patient, that patient is no longer at risk for upgrading. Figure 1 shows that UCSF had the highest cumulative incidence of disease upgrading, JHU had the lowest, and PASS and UT were between UCSF and JHU. In contrast, the JHU cohort had the highest risk for competing treatment, possibly due to the relatively high incidence of reclassification by only volume, which accounts for about half of the reclassified patients (4), whereas the other cohorts had similar, lower risks for competing treatments.
Risks for Upgrading and Associations With Baseline PSA and PSA Velocity
Exploratory plots show a range of PSA profiles across 3 selected patients from each cohort, illustrating that the PSA models captured the observed diversity (Supplement Figure 2 , available at Annals.org). Mean PSA velocity was similar across cohorts, with estimated annual increases of 5% (95% CI, 4% to 6%) for JHU, 6% (CI, 4% to 7%) for PASS, 8% (CI, 6% to 9%) for UT, and 7% (CI, 6% to 8%) for UCSF. Across cohorts, men with higher PSA levels tended to have higher risks for upgrading, as indicated by the baseline PSA (intercept) or PSA velocity (slope) significantly associated with the risk for upgrading in every cohort (Supplement Table 2 , available at Annals.org). Older men tended to have higher risks for upgrading, most notably in the JHU and UT studies, and lower risks for treatment, most notably in JHU. Figure 2 shows the estimated cumulative risks for upgrading by year in the absence of competing treatments as derived from the joint model, where disease was considered to be upgraded in the interval between a last negative biopsy result (no cancer or GS ≤6) and a first positive biopsy result (GS ≥7). (Supplement Figure  3 , available at Annals.org, shows empirical KaplanMeier curves in which upgrading occurs at the first observed biopsy GS ≥7.) Whereas the upgrading risk was still highest in UCSF and lowest in JHU, the risk in UT closely matched that in PASS, in contrast to the empirical results in Figure 1 . This convergence is due to the interval censoring, which affected the estimates from UT more than those from other cohorts because of its longer surveillance intervals.
Annual Risks for Upgrading
Supplement Figure 4 (available at Annals.org) shows the estimated cumulative risks for upgrading in the absence of competing treatments for a man aged 60 years at entry with specified values for baseline PSA and PSA velocity. Conditional on his PSA kinetics, comparisons across cohorts may shift. Upgrading risks were closer in the PASS, UCSF, and UT cohorts for lower PSA levels (3 μg/L) at entry, but the curves fanned out for men with higher PSA levels (6 μg/L) at entry, with the UCSF study showing a marked increase in the risk for upgrading with baseline PSA level. This finding is consistent with Supplement Table 2 , which shows a stronger positive association between PSA at entry and the Upgrading in Four Prostate Cancer Active Surveillance Cohorts ORIGINAL RESEARCH risk for upgrading in UCSF than in the other cohorts. Even when age and PSA kinetics were held constant, the JHU cohort had a lower risk for upgrading than the other cohorts. Table 3 shows model-predicted outcomes over a range of surveillance intervals. For example, on average biennial biopsies starting at enrollment reduced the number of biopsies relative to annual biopsies by 42% to 48% but delayed detection of upgrading by 6 to 8 months. Biennial biopsies starting after the first confirmatory biopsy (1 year after enrollment) reduced the number of biopsies relative to annual biopsies by 32% to 38% but delayed detection of upgrading by only 3 to 5 months. Table 4 provides more detail about annual versus biennial surveillance protocols. Except for year 1, annual probabilities of upgrades were reasonably constant. Thus, although both biennial strategies materially reduced the number of biopsies, biennial surveillance starting after a first confirmatory biopsy may represent a more acceptable balance. To assess the clinical consequences of detection delays, we show in Supplement Figure 5 (available at Annals.org) that the hazard of prostate cancer death increases with delayed detection relative to the point of true upgrading. However, for the range of delays assessed (1 to 4 years), this increase is less than 3% across cohorts. Although this long-term prediction provides a useful benchmark, it assumes that other prognostic covariates (for example, volume) remain constant during the delay.
More Versus Less Intensive Surveillance Protocols
DISCUSSION
Active surveillance continues to evolve and gain acceptance as a strategy for managing low-risk prostate cancer, but consensus on an optimal protocol is lacking (10). To inform any consensus, we need a representative assessment of the extent to which patients with prostate cancer on AS face risks for disease progression and adverse downstream outcomes. This study is the first to our knowledge to bring together individuallevel data across AS studies for such an assessment.
Integrating evidence across AS studies means confronting major differences in inclusion criteria, protocols, and end points, as well as addressing differences in competing treatment. All of these differences materially affect published risks for progression. However, even when we level the playing field in terms of inclusion criteria, surveillance intervals, and end points and present results in the absence of competing treatment, fundamental differences exist in underlying risks for biopsy upgrading across cohorts. Indeed, the estimated 10-year cumulative risk for upgrading in the absence of competing treatments ranges from 25% (JHU) to 65% (UCSF).
How can we explain these persistent differences? They may be partly explained by minor differences in the biopsy cores sampled but are more likely due to variations in the profiles of entering patients that are not captured by the characteristics measured in this study. For example, most JHU patients were at very low risk, with PSA densities less than 0.15 μg/L per mL. Because low PSA density may result from a higher prostate volume, the chance of identifying high-grade foci could have been reduced. This is supported by the results of imposing this condition on PASS patients (the only other cohort that recorded this information), approximately 75% of whom had PSA densities less than 0.15 μg/L per mL. Although the estimated risk for upgrading in this subset was modestly lower than that in the whole cohort (Supplement Figure 6 , available at Annals.org), it did not become similar to the risk in the Years From Diagnosis Cumulative Probability
For each curve, we assume that baseline PSA and PSA velocity are fixed at cohort-specific mean values. Estimates accommodate interval censoring for biopsy upgrading between the last negative and first positive biopsy results. JHU = Johns Hopkins University; PASS = Canary Prostate Active Surveillance Study; PSA = prostate-specific antigen; UCSF = University of California, San Francisco; UT = University of Toronto.
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Upgrading in Four Prostate Cancer Active Surveillance Cohorts JHU cohort. The low risk for upgrading in the JHU cohort may also reflect other factors associated with selection into this cohort, such as biopsy volume. The JHU study restricted enrollment to patients with 2 or fewer cores with cancer and at most 50% involvement of every core, whereas UCSF allowed up to 33% of cores containing cancer and included some patients with higher volumes.
Our results indicate that a single AS study may not reflect the risks for prostate cancer progression in another population. Nonetheless, our analysis suggests that the consequences of varying the intensity of surveillance are highly robust across levels of underlying risk. For example, biennial biopsies starting at enrollment will detect upgrading on average only 6 to 8 months later than annual biopsies, a delay that is unlikely to substantially increase risk for adverse downstream outcomes on the basis of our assessment and published studies of treatment delays in low-to moderate-risk patients (18, 19) . Biennial biopsies starting after a confirmatory biopsy (1 year after enrollment) result in even shorter expected delays.
A crucial assumption of our analysis was that the risks for upgrading and competing treatment are independent given patient age and PSA kinetics and that no other factors correlate with these events.
A key limitation of this work is that we considered only biopsy upgrading rather than true pathologic upgrading. Because of potential misclassification, biopsy grade may not capture true pathologic grade, which is a better surrogate for aggressiveness. We previously showed (16) that we cannot identify the true grade trajectory from serial biopsies on AS even if we know the misclassification probabilities. Thus, grade progression is defined as the first biopsy with a GS of at least 7, and our analysis did not allow grade to have progressed before the last biopsy with a GS between 2 and 6. Our analysis also did not allow for false-positive biopsy results or address other questions of interest, such as the inclusion of patients with a GS of 3 + 4 = 7, optimal ages of enrollment, or the appropriateness of AS for African American men. Finally, we did not address questions about magnetic resonance imaging or novel biomarkers for predicting disease progression or aggressiveness; further research is needed to tailor surveillance protocols to underlying or evolving risk for progression.
In conclusion, our analysis reveals practical challenges to medical decision making and guideline development around AS. In particular, risks for cancer upgrading do not generalize from 1 cohort to another even after we control for differences in eligibility criteria, surveillance protocols, and competing treatments. However, expected delays in detecting upgrading under more versus less intensive protocols are robust across cohorts. Our analysis suggests that biennial (2) , which also recommends less frequent biopsies after a confirmatory biopsy within a year of entering AS. Both that guideline and our analysis support less frequent biopsies for men receiving AS, which should reduce morbidity and complications of this conservative approach as it becomes further established as a preferred method for managing low-risk prostate cancer.
